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ABSTRACT
With the high prevalence of bothersome lower 
urinary tract symptoms (LUTS) in older men, 
clinical management has to be fairly simple 
and straightforward. In the absence of severe 
problems requiring immediate action, and after 
excluding possible other etiological factors by a 
simple diagnostic algorithm, the key parameter 
for therapeutic decisions is the severity of 
LUTS, in particular the degree of annoyance 
and irritation, and prostatic enlargement. 
Patients with bothersome LUTS request rapid 
improvement but also worry about possible 
deterioration, complications, and the need for 
surgery. With a prostate volume above 30–40 mL 
and/or prostate-specific antigen (PSA) serum 
>1.5 ng/mL, the combination of an alpha-1 
blocker with a 5-alpha-reductase inhibitor 
(5-ARI) should be first-line treatment. With 
prostates <30 mL at baseline the issue whether 
the prostate really is the culprit becomes 
central. Given the rapid onset of action of 
alpha-1 blockers, a 4–6-week trial appears to 
be a logical approach. If the International 
Prostate Symptom Score does not improve 
and storage symptoms prevail, an overactive 
bladder appears more likely as causative factor 
and antimuscarinics are the next step. Based on 
available data this is recommended as add-on 
medication to the alpha-1 blocker. With no 
improvement, or increasing postvoid residual 
the diagnostic algorithm needs to be revisited 
and more extensive urodynamic evaluation may 
be needed.
Keywords: 5-alpha-reductase inhibitors; Alpha-1 
adrenoceptor antagonists; Benign; Combination 
therapy; LUTS; Prostate enlargement; Urology
INTRODUCTION
Lower urinary tract symptoms (LUTS) are a 
common problem in older men that increases 
steeply with age [1, 2]. Approximately 50% of 
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men 70–80 years of age report moderate-to-
severe LUTS, with significant bother, and 
impact on quality of life [3–5]. They can 
be subcategorized into storage symptoms 
(frequency, urgency, nocturia, urinary 
incontinence), voiding symptoms (slow 
stream, splitting, intermittency, hesitancy, 
straining, dribble), and postmicturition 
symptoms (sensation of incomplete emptying, 
postmicturition dribble), and can be quantified 
with validated and internationally accepted 
questionnaires, the International Prostate 
Symptom Score (IPSS) being most widely 
used [6, 7]. Infravesical obstruction by benign 
prostatic enlargement (BPE) resulting from 
benign prostatic hyperplasia (BPH) has been 
assumed to be the main cause of the problem. 
Indeed, 48–60% of men >60 years of age seen by 
general practitioners have a clinically enlarged 
prostate and approximately one third have 
both moderate-to-severe LUTS and an enlarged 
prostate [3, 8]. Larger prostate volume has 
been correlated with more severe LUTS and a 
higher risk of progression of symptoms and 
complications [9]. The etiology of LUTS is in 
fact more complex and multifactorial [6, 7, 10]. 
Renal factors such as polydipsia or nocturnal 
polyuria and/or abnormal bladder function 
such as detrusor overactivity are presumably 
equally important factors, and in general 
overlap in any single individual. Even in 
patients with urodynamically proven benign 
prostatic obstruction (BPO) the association 
between symptoms, quality of life, and objective 
urodynamic parameters remains weak. Clearly 
the mechanisms involved are interactive: 
storage symptoms suggestive of an overactive 
bladder (OAB) increase with the degree of 
outflow obstruction [10], but bothersome 
LUTS persist in 20–40% of patients even after 
surgical correction of urodynamically confirmed 
BPO [11].  
The patient consulting his doctor because of 
LUTS primarily seeks relief from his symptoms, 
but he also worries about further deterioration 
and complications requiring more invasive 
treatment such as surgery. This is not without 
foundation; LUTS assumed to be caused by BPH 
are progressive over time [9,12] and the overall 
risk of acute urinary retention in population 
studies has been estimated at up to 23% for an 
average 60-year-old man if he survives another 
20 years [13].
In view of the high prevalence of bothersome 
LUTS the diagnostic approach to the problem 
has to be fairly simple and straightforward. In 
general, a thorough history (with quantification 
of symptoms and quality of life issues; IPSS), 
a voiding chart (the physician should rule out 
nocturia, polyuria, and polydipsia), physical 
examination (with digital rectal examination of 
the prostate), urinalysis, determination of serum 
prostate-specific antigen (PSA), ultrasonography 
of the bladder, prostate, upper urinary tract (with 
determination of postvoid residual urine), and 
uroflowmetry provide all information needed for 
therapeutic decisions, at least on a nonsurgical 
level [2]. In men >50 years of age with an 
IPSS >7, no evidence of excessive nocturia, an 
enlarged prostate, maximum urinary flow rates 
<12 mL/sec, and postvoid residual urine <150 mL, 
BPO resulting from prostatic enlargement is the 
most likely cause of the problem [14]. Serum 
PSA levels >1.5 ng/mL have also proven fairly 
reliable surrogate markers of BPE once cancer is 
excluded [15]. Prostate volume and serum PSA 
are the most reliable prognosticators for the risk 
of symptom progression and the occurrence of 
complications such as acute urinary retention or 
the need for surgery [16].
Mild LUTS (IPSS ≤7) can usually be managed 
with simple lifestyle advice, such as avoiding 
excessive fluid intake and moderating caffeine 
and alcohol consumption [17]. With an 
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IPSS >7, consistent with moderate-to-severe 
LUTS, and clinical findings as described above, 
medical therapy becomes the first line of 
management [6, 18, 19].
METHODS
The findings presented here are an interpretation 
of the present literature, and not the result of a 
systematic literature search by the author, which 
also reflects the situation of most guidelines on 
this topic [6, 18, 19].
DISCUSSION 
Single-Agent Therapy
Alpha-1 Adrenoceptor Antagonists (Alpha-1 
Blockers)
Contraction of the smooth muscle of the 
prostate and bladder neck by endogenously 
released noradrenaline is primarily regulated by 
alpha-1A adrenoceptors, although alpha-1B and 
alpha-1D subtypes in the bladder and nervous 
system may also play a role [20, 21]. Blocking 
these receptors with alpha-1 blockers results in 
rapid reduction of symptoms by approximately 
30–40% and improvement of flow rates by 
approximately 20%, but disease progression is 
not avoided in the long term and there is no 
decrease in prostate volume or the likelihood of 
acute urinary retention [6, 9, 22]. 
The therapeutic efficacy of all alpha-1 
blockers currently licensed for the treatment 
of LUTS assumed to be caused by BPH appears 
fairly similar [23, 24], but their adverse effect 
profiles differ significantly, apparently due to 
their variable alpha-1 receptor subselectivity. 
Older agents, such as doxazosin and terazosin, 
also affect alpha-1B adrenoceptors in blood 
vessels and dosage has to be titrated according to 
individual tolerance. Alfuzosin, tamsulosin, and 
silodosin have less vasodilating effects and hence 
cause less asthenia, dizziness, and orthostatic 
hypotension. There is no significant impact on 
libido or erectile function, but tamsulosin and 
in particular silodosin may cause an absence 
of ejaculation, apparently due to a distinctly 
higher specificity to alpha-1A receptors [25]. 
Alpha-1 blockers, in particular tamsulosin, have 
been shown to cause intraoperative floppy iris 
syndrome at cataract surgery; therefore, they 
should be stopped well ahead of the procedure, 
and the ophthalmologist informed [26].
It is, at present, common consensus in major 
guidelines that alpha-1 blockers should be 
offered to men with moderate-to-severe LUTS 
based on level 1a evidence [6, 18, 19]
5-alpha-Reductase Inhibitors
BPH causing prostatic enlargement is androgen 
driven and at the cellular level this is mainly 
mediated by dihydrotestosterone (DHT). 
Testosterone is converted to DHT by the nuclear-
bound steroid enzyme 5-alpha reductase. 
If blocked, this mechanism is interrupted 
without impairing androgen activity outside 
of the prostate. 5-alpha reductase exists in two 
isoenzymes; type 2 is predominantly expressed in 
benign prostatic tissues and type 1 mainly in skin 
and liver, but also in prostate cancer cells [27–29]. 
Two 5-alpha-reductase inhibitors (5-ARIs) are 
approved for the treatment of LUTS considered 
to be caused by BPE from BPH, finasteride, 
and dutasteride. Finasteride blocks only the 
type 2 isoenzyme and reduces serum DHT at 
a dosage of 5 mg/day by approximately 70%. 
Dutasteride inhibits both isoenzymes and at 
a dose of 0.5 mg/day decreases serum DHT 
levels by more than 90% [27, 28]. Inactivation 
of the androgen receptor results in apoptosis 
of prostate epithelial cells. Within 6 months, 
PSA levels fall by approximately 50% and, by 
approximately 12 months, prostate volume 
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decreases by 18–28% [30]. This is paralleled by 
an improvement in LUTS after approximately 
9 months of treatment, with gradually improving 
flow rates [31–33]. A direct head-to-head 
comparison of finasteride and dutasteride with a 
follow-up of 12 months showed no difference in 
efficacy [34]. In the Medical Therapy of Prostatic 
Symptoms (MTOPS) trial, finasteride was inferior 
to doxazosin in preventing symptom progression 
at a mean follow-up of 4.5 years [9]. In contrast, 
dutasteride monotherapy in the Combination of 
Avodart and Tamsulosin (CombAT) trial proved 
more effective than tamsulosin monotherapy 
at 4 years, with an increasing advantage over 
time after 15 months of therapy (Fig. 1) [35–37]. 
The two studies are not fully comparable,
as primary endpoints and the alpha-1 blockers 
used for comparison were different and in spite 
of similar mean LUTS scores at baseline CombAT 
patients were at higher risk of progression 
because of significantly higher baseline prostate 
volumes and PSA levels. In both studies, 5-ARI 
therapy achieved a dramatic reduction of 
acute urinary retention rates and the need for 
surgery, which was not observed with alpha-
blocker monotherapy. The impact on symptoms, 
flow rates, and the reduction of acute urinary 
retention was most pronounced in patients with 
the highest prostate volume and PSA levels, 
thus defining patients that are at highest risk of 
progression and complications, and who clearly 
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Fig. 1  CombAT study: Mean adjusted change in International Prostate Syndrome Score (IPSS; plus or minus 
standard error) from baseline by visit and treatment group. Reproduced with permission om Montorsi F, Roehrborn C, 
Garcia-Penit J, et al. e eects of dutasteride or tamsulosin alone and in combination on storage and voiding symptoms in men 
with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH): 4-year data om the Combination of 
Avodart and Tamsulosin (CombAT) study. BJU Int. 2011;107:1426–31. * P < 0.001 for combination versus tamsulosin. 
** P < 0.001 for combination versus dutasteride
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5-ARIs are generally well tolerated. The most 
common adverse events observed in placebo-
controlled studies were loss of libido and erectile 
dysfunction in approximately 5% of patients and, 
less commonly, abnormal ejaculation [9, 32, 33]. 
The magnitude of these problems has to be seen 
against frequent sexual dysfunction in patients 
with LUTS. In a large population-based study 
18% of men 70–80 years of age with moderate-
to-severe LUTS reported severe erectile 
dysfunction [41]. A small percentage of men 
develop gynecomastia [31, 36, 42, 43], but a 
statistically significant incidence of malignant 
breast tumors has not been observed in any 
prospective controlled 5-ARI trials.
In prospect ive,  placebo-control led 
chemoprevention trials, both finasteride [44] 
and dutasteride [45] reduced the incidence of 
low-grade prostate cancer, but the systematic, 
study-driven biopsies revealed a slightly higher 
incidence of high-grade, Gleason score 8–10 
prostate cancer in the 5-ARI arms. This was 
not observed in real-life studies in patients 
being treated for LUTS, such as the CombAT 
trial [36], where biopsies were only performed 
when clinically indicated. Plausible explanations 
for the higher detection of high grade cancers 
in the chemoprevention trials are the better 
diagnostic accuracy of biopsies in smaller 
prostates, an increased sensitivity of PSA testing 
in patients on 5-ARIs, and possibly a more 
pronounced effect of 5-ARI on low-grade than 
on high-grade cancers [46, 47]. Patients should 
remain under surveillance in this context. The 
key to this issue is understanding the altered 
PSA dynamics in patients on 5-ARIs. PSA levels 
decrease continuously with long-term 5-ARI 
medication, rendering the simple “doubling 
rule” (to compare PSA levels to the values of 
men not on 5-ARIs) unreliable [46, 47]. A first 
PSA measurement should be obtained after 
6 months of 5-ARI medication and this becomes 
the new baseline value for future comparison. 
PSA is monitored at regular intervals thereafter 
(in general every 6 months) and any confirmed 
increase from the lowest value measured 
thereafter, a “nadir,” should be considered a 
warning flag of possible cancer and trigger the 
appropriate diagnostic measures [48].
Antimuscarinics
Although older men with BPE report a higher 
prevalence of voiding than storage symptoms, 
the latter are more bothersome and tend to 
affect quality of life more profoundly [5]. 
Given the high prevalence of concomitant 
detrusor overactivity and OAB in men with 
BPE [10] it would seem logical to treat men 
with predominant storage symptoms with 
muscarinic receptor antagonists, i.e., bladder-
specific drugs. The obvious concern with this 
approach is that antimuscarinics improve 
urgency, but lower voiding pressure, increase 
postvoid residual, and may ultimately trigger 
acute urinary retention. Prospective, controlled 
studies with antimuscarinic monotherapy in 
men with urodynamically proven bladder outlet 
obstruction and OAB have not confirmed these 
risks, but usually only showed improvement in 
subgroup analyses of symptoms of no, or only 
marginal, clinical significance [49–51]. Patients 
with high postvoid residual, low flow rates, and 
severe obstruction were usually excluded in these 
studies and follow-up was limited to 6–12 weeks. 
Patients with small prostates and/or PSA levels 
<1.3 ng/mL seem to benefit more [52], but 
there is general agreement that antimuscarinic 
monotherapy should be approached with 
caution in men with LUTS and BPE; close 
urologic surveillance is mandatory [6, 18, 19].
Phosphodiesterase-5 Inhibitors 
Prospective, placebo-controlled, randomized 
trials have shown that phosphodiesterase-5 
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inhibitors (PDE-5 Is) improve LUTS in men
assumed to be caused by BPO [53, 54]. Biologically
active PDE-5 is expressed in the musculature 
of the bladder neck, prostatic urethra, and 
prostate [55], and its inactivation had been 
postulated to relieve outflow obstruction until 
this was disproven by Dmochowski et al [56]. This 
has not really been confirmed urodynamically, 
and more complex mechanisms affecting 
an increased bladder/prostate afferent 
activity may also play a role [56]. A recent 
systematic analysis of seven prospective studies 
comparing PDE-5 Is monotherapy versus 
placebo in >2,000 men demonstrated consistent 
improvement of LUTS and erectile function, but no 
change in flow rates [57]. Symptom improvement 
was similar across all PDE-5 Is and dosages studied. 
Younger men with lower body mass index and 
more severe LUTS seemed to benefit most. Adverse 
events were consistent with those documented 
in the treatment of erectile dysfunction and 
mainly consisted of flushing, gastroesophageal 
reflux, dyspepsia, and headache [57]. All studies 
were limited by short duration, usually 12 weeks, 
and the lack of adequately powered direct 
comparison to approved agents, such as alpha-1 
blockers [57, 58]. Although PDE-5 Is are already 
approved for the treatment of male LUTS in the 
US and Europe, recent guidelines still suggest that 
they be used cautiously [6, 18, 19].
Phytotherapy
A wide spectrum of plant extracts are being 
marketed for the treatment of LUTS across 
the world. Their pharmacokinetic properties 
are highly variable, in general poorly defined, 
and rarely studied in adequately powered 
prospective trials. The European Association of 
Urology guidelines on the management of non-
neurogenic male LUTS analyzed in detail the 
phytotherapeutic products marketed in Europe 
and concluded that ‘no phytotherapeutic agent 
has been shown to significantly reduce prostate 
size and no trial has proven reduction of 
bladder outlet obstruction or decreased disease 
progression’ [6].
Combination Therapy
Given the complex and multifactorial etiology 
of LUTS and clear limitations of all single-agent 
approaches combining drugs with different 
modes of action to achieve synergistic effects 
appears a logical development [58].
Alpha-1 Blockers and 5-ARIs
Alpha-1 blockers provide rapid symptom 
improvement within weeks, but cannot prevent 
disease progression and acute urinary retention. 
5-ARIs achieve the latter, but take months 
to alleviate symptoms. Combining the two 
achieves both treatment objectives of rapid 
relief of symptoms and reducing the risk of 
progression. Long-term treatment is prerequisite, 
the advantage of combining the two classes 
of agents has only been demonstrated with 
treatment >12 months, and the advantage 
becomes more pronounced the longer it is 
administered [9, 36, 58]. Patients at higher risk 
of progression, e.g., with larger prostates and/or 
higher PSA levels, profit more. 
The CombAT trial compared tamsulosin 
versus dutasteride versus the combination 
of both in patients with ≥12 IPSS, prostate 
volumes ≥30 mL, and serum PSA ≥1.5 ng/mL. 
Combination therapy resulted in better symptom 
improvement than tamsulosin monotherapy 
already after 9 months of therapy, and the 
difference increased with ongoing treatment 
(Fig. 1) [35–37, 39]. Similar advantages were seen 
in improvements of storage and voiding IPSS 
subscales and flow rates and time to symptom 
progression [37, 39]. Urinary retention rates 
were lower with combination therapy than with 
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tamsulosin monotherapy already after 8 months, 
and continued to diverge linear to a relative 
reduction of 68% at 4 years [35, 36]. Patients 
with larger prostates at baseline clearly profited 
most, and symptom improvement was superior 
when comparing tamsulosin monotherapy 
with combination therapy from month 21 in 
the lowest volume tertile (30–42 cm3), from 
month 6 in the middle volume tertile, and 
from month 3 in the highest volume tertile 
(>58 cm3) [35, 39]. In the MTOPS trial, the 
combination of doxazosin and finasteride was 
compared to monotherapy and placebo. Patients 
included in the study had lower prostate 
volumes and PSA levels at baseline than in 
the CombAT trial, but the results were similar; 
combination therapy was significantly more 
effective in preventing disease progression, with 
the advantages more pronounced in the patients 
with larger prostates at baseline [9, 38, 40].
The adverse events observed with 
combination therapy are additive, and as a 
consequence more common than with either 
single agent. They reflect the adverse event 
profile of each class of agents. Serious adverse 
events were, however, rare (<1%) in these 
studies, and comparable in the combination 
and monotherapy arms, with similar study 
withdrawal rates [9, 36].
Recent guidelines recommend the combination 
of an alpha-1 blocker and an 5-ARI as first-line 
treatment of men with moderate-to-severe LUTS 
and an enlarged prostate, although the definition 
of “enlarged” varies from no precise definition [6] 
to prostate volumes >30–40 mL [18, 19]. Differing 
opinions on this issue only exist on the lower 
cut-off value of prostate volume above which 
this combination becomes the first-line therapy. 
A posthoc subanalysis of MTOPS data suggested 
advantages over alpha-1 blocker monotherapy 
already at baseline prostate volumes >25 cc [40]. 
In the CombAT trial, patients had to have a 
prostate volume >30 mL to be admitted to the 
study; combination therapy reduced symptom 
deterioration across all baseline subgroups, 
but this did not reach statistical significance at 
prostate volumes <40 mL [39]. With an inherent 
variation of prostate volume measurements 
by ultrasonography of about ± 15% a precise 
threshold is clinically probably overstated. 
Therefore, the larger the prostate the higher 
the risk of disease progression and the more 
pronounced the benefits of combining an alpha-1 
blocker with an ARI with long-term treatment.
Alpha-1 Blockers and Antimuscarinics
In the first major prospective randomized trial 
by Kaplan et al., the combination of tolterodine 
and tamsulosin was compared against either 
single agent and placebo in patients with 
an IPSS ≥12 and explicit bothersome storage 
symptoms (≥3 urgency episodes per day) [50]. 
Total IPSS and the patient-reported treatment 
benefit after 12 weeks of therapy showed 
significant improvement in the combination 
arm, whereas tamsulosin alone only improved 
the total IPSS and tolterodine alone showed no 
improvement of either [50]. The improvement 
in quality of life with combination therapy 
was dominated by the improvement in storage 
symptoms, in particular 24-h voiding frequency. 
Similar messages come from studies in which 
an antimuscarinic agent is added to an alpha-1 
blocker, usually after an insufficient response; 
storage symptoms improve at no increased 
risk of acute urinary retention [59–61]. All of 
these studies tended to include patients with 
predominantly storage symptoms and excluded 
patients with significant postvoid residual and/or 
low flow rates at baseline. Patient numbers are 
often too small for valid statistical comparison 
of the different treatment arms and follow-up 
is usually short. The typical adverse events of 
anticholinergic medication, such as dry mouth 
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and constipation, usually also resulted in higher 
withdrawal rates in the combination arms 
than in alpha-blocker monotherapy or placebo 
add-on arms [52, 58].
Alpha-1 Blocker and PDE-5 Is
Combining an alpha-1 blocker with sildenafil/
tadalafil has been shown to improve 
symptom scores, flow rates, and erectile 
function [53, 57, 58]. Side effects were only 
marginally increased. Both studies were only 
powered to compare the results to baseline, 
and not between groups. Overall, the data are 
insufficient to document a clear advantage of 
this combination in comparison to alpha-1 
blocker monotherapy in the typical LUTS 
patient. Nevertheless, being able to add a 
PDE-5 inhibitor to an alpha-1 blocker without 
major problems, and possibly advantages, is an 
important message in this population given that 
over 50% (approximately) patient group have 
problems with erectile dysfunction [41].
CONCLUSION
In men with moderate-to-severe LUTS and 
a prostate volume >30–40 mL and/or serum 
PSA >1.5 ng/mL, the combination of an 
alpha-1 blocker with a 5-ARI should be first-
line treatment today. In men with  prostates 
<30 mL at baseline, the issue whether the 
symptoms are really caused by bladder outflow 
obstruction becomes more central. Once other 
obvious reasons for LUTS, such as urinary 
tract infection, bladder tumors, urethral 
strictures, obvious neurogenic dysfunction, 
and postvoid residuals >250 cc, have been 
ruled out a 4–6-week trial of therapy with an 
alpha-1 blocker appears a logical approach. If 
IPSS does not improve, and storage symptoms 
prevail, an OAB appears more likely as causative 
factor and antimuscarinics are the next step. 
Based on available data this is recommended as 
add-on medication to the alpha-1 blocker. With 
no improvement, or increasing postvoid residual 
the diagnostic algorithm needs to be revisited 
and more extensive urodynamic evaluation may 
be needed.
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